The First Major For-Profit Psychedelic Company Is Experiencing Major Setbacks

Tue, Dec 10

Has the psychedelic hype bubble burst? Compass Pathways announced major layoffs, delays in psilocybin trials, and a sharp stock plunge amid losses. The biotech giant now faces tough questions. So, what does this mean for the future of psychedelic therapy? https://t.co/h9G6N8qRJY

10715

Compass Pathways is laying off employees and delaying its Phase 3 trials, signaling growing economic pressures and a changing public perception of psychedelic medicine.

Discover